News & Resources / All News

Singapore Health Sciences Authority (HSA) Greenlight Veredus Laboratories’ Saliva Testing for COVID-19 as In Vitro Diagnostic (IVD) Use

Singapore, Dec 02, 2020 – Veredus Laboratories Pte Ltd “Veredus” has obtained Provisional Authorisation from Singapore Health Sciences Authority (HSA) for ZeroPrep™ Saliva Collection Kit and extraction-free VereRT™ ZeroPrep™ COVID-19 PCR Kit for use in combination as an In Vitro Diagnostic (IVD) test for COVID-19 in Singapore. This follows Veredus’ launch extraction-free RT-PCR test using saliva as a Research Use Only (RUO) test earlier. Veredus can now supply to healthcare institutions, private hospitals, medical clinics and clinical laboratories licensed under the Private Hospitals and Medical Clinics (PHMC) Act (Cap. 248) for use on
their patients in Singapore.

ZeroPrep™ Saliva Collection Kit is a specimen device intended for the collection of human saliva. When used in conjunction with VereRT™ ZeroPrep™ COVID-19 PCR Kit, the saliva specimen can be tested for COVID-19. In addition to saliva, VereRT™ ZeroPrep™ COVID-19 PCR Kit is an RNA extraction-free IVD test that can also be used with nasopharyngeal swab.

Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories said, “This is another great achievement for Veredus. We are very proud and at the same time, grateful for the Authority to approve our product as the first human saliva-based IVD test for COVID-19 in Singapore. We believe our extraction-free saliva test method is also amongst the world’s first diagnostic product for COVID-19 using human saliva instead of conventional nasopharyngeal swab. With aims to facilitate massive COVID-19 testing via non-invasive specimen collection method, we also want to support laboratories with quicker and more efficient ways to strengthen their diagnostic effort for COVID-19.”

[AACC TV] Veredus Laboratories – COVID-19 Biosurveillance in Singapore and Beyond

SGTi-flex COVID-19 Ag Receives Provisional Authorisation from the Health Sciences Authority (HSA) in Singapore for In vitro Diagnostic (IVD) Use

Veredus Laboratories Pte Ltd “Veredus” is the appointed distributor of Sugentech, Inc. to market and sell SGTi-flex COVID-19 Ag.

Veredus has obtained Provisional Authorisation from Singapore Health Sciences Authority (HSA) to supply SGTi-flex COVID-19 Ag for use as an In vitro Diagnostic (IVD) test in Singapore. Veredus can now support healthcare institutions, private hospitals, medical clinics and clinical laboratories licensed under the Private Hospitals and Medical Clinics (PHMC) Act in Singapore.

SGTi-flex COVID-19 Ag is a one step, rapid Immunochromatographic Assay for the qualitative detection of specific antigens belonging to SARS-CoV-2 present in human nasopharyngeal (or oropharyngeal) swab specimen.

For more information, please visit our COVID-19 page or contact us at info@vereduslabs.com.

Medlab Asia & Asia Health Virtual Edition

Join us at the largest virtual healthcare tradeshow of its kind in the ASEAN region on 20 – 22 October 2020. There will be networking opportunities for you to talk to our team members to find out more on our products.

Register for free now at https://www.medlabasia.com/en/home.html and see you there!

Veredus Laboratories Launches Next Generation COVID-19 Diagnostic Test Using Samples Directly from Saliva or Swab

Veredus Laboratories Pte Ltd (“Veredus”) announced today the launch of its Extraction-free RT-PCR Suite consisting of VereRT™ COVID-19 PCR Kit (formerly known as VereRTCoV™ SARSCoV-2 Real-Time RT-PCR 2.0) for direct use either on human saliva (ZeroPrep™ Saliva Collection Kit, formerly known as VereRTCoV™ ZeroStep Saliva Collection Kit) or from swab (ZeroPrep™ Swab Buffer Kit).

Saliva Test – ZeroPrep™ Saliva Collection Kit, when used in conjuction with VereRT™ COVID-19 PCR Kit, is intended for direct testing on human saliva for COVID-19 diagnosis. This specimen collection method is non-invasive as saliva can be obtained easily without assistance as compared to nasopharyngeal swab where trained medical personnel is required to perform the swabbing procedure. This reduces manpower and eliminates their exposure to the virus. ZeroPrep™ Saliva Collection Kit is able to collect human saliva as a specimen for COVID-19 diagnosis as it has a specially formulated preservation buffer to stablise and preserve viral RNA, enabling it to be used directly in the PCR test without the need for nucleic acid extraction as an intermediate step.

Swab Test – The current prevalent COVID-19 screening regime relies heavily on nasopharyngeal swab test, where the specimen is obtained and deposited in transport media before being sent to the testing laboratory. Upon receiving the specimen, the initial step of molecular diagnosis is to extract the genetic material from the virus followed by DNA amplification to identify SARS-CoV-2 responsible for COVID-19.

VereRT™ COVID-19 PCR Kit, when used in conjunction with ZeroPrep™ Swab Buffer Kit, is a next generation PCR-based In Vitro Diagnostic (“IVD”) test for COVID-19. It shortcuts the testing workflow by eliminating the nucleic acid extraction process as the operator is able to perform the diagnostic test directly from the swab. By eliminating the extraction phase which comprises of several laborious steps, it results in cost- and timesaving, as well as a reduction in vulnerability to supply chain shortages especially during high-volume testing by laboratories globally.

VereRT™ COVID-19 PCR Kit has obtained CE-IVD marking and Provisional Authorization from Health Sciences Authority (HSA) Singapore for use as an IVD test for supply to hospitals and medical clinics for use on patients to diagnose COVID-19 in Singapore.

“Veredus is innovating rapidly and we are excited to be one of few companies offering direct PCR testing using saliva or swab without the need for viral RNA extraction. This method of direct COVID-19 testing is the next step for us as we seek to increase the testing capacity of healthcare authorities and laboratories by reducing workflow complexity in COVID-19 molecular testing.” said Dr. Rosemary Tan, Chief Executive Officer of Veredus Laboratories.

Veredus Laboratories Launches VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 as CE-IVD Test Kit for Diagnostic Use across Europe

Veredus Laboratories Pte Ltd “Veredus” has received CE-IVD marking for VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 as a molecular diagnostic test kit to be used in clinical practice across Europe and other countries that recognize the CE Mark. This announcement follows the recent commercial launch of this IVD test with approvals from Health Sciences Authority (HSA) Singapore and Philippines FDA.


VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is a one-step Reverse Transcription Polymerase Chain Reaction (RT-PCR)-based IVD test intended for the qualitative detection of nucleic acid belonging to SARS-CoV-2.


“We are very pleased with the European launch of our test and for Veredus to reach out beyond South East Asia and into the European region to support countries in need for molecular test to detect and identify the SARS-CoV-2 virus. At the same time, with this CE-IVD marking, we can now plan for immediate rollout to healthcare institutions around the world for diagnostic use. Veredus is commited to join the fight against COVID-19 and will continue to help move precision testing forward,” said Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.

The Food and Drug Administration (FDA) of the Philippines has Approved Veredus Laboratories’ VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 for Commercial Use as an IVD Test for COVID-19

Singapore, June 15, 2020 – Veredus Laboratories Pte Ltd “Veredus” announced that the VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is now approved for commercial use as an In vitro Diagnostic (IVD) test in the Philippines by the Food and Drug Administration (FDA). This product was also authorised by the Singapore Health Sciences Authority (HSA) in early June for supply to hospitals and medical clinics for use on patients to diagnose COVID-19.

VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is a one-step Reverse Transcription Polymerase Chain Reaction (RT-PCR)-based IVD test intended for the qualitative detection of nucleic acid belonging to SARS-CoV-2.

“Veredus is very appreciative for the Philippines FDA to recognise and approve our RT-PCR test to be used as an IVD device in the country. We are motivated in reaching out beyond Singapore to introduce our diagnostic solutions in different parts of the world. With this, we hope to join the ecosystem and contribute vastly in the global fight against COVID-19” said Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.

Veredus Laboratories’ VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 Receives Provisional Authorisation from the Health Sciences Authority (HSA) in Singapore for In vitro Diagnostic (IVD) Use

Veredus Laboratories Pte Ltd “Veredus” has obtained Provisional Authorisation from Singapore Health Sciences Authority (HSA) for VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 for use as an In vitro Diagnostic (IVD) test in Singapore. Veredus can supply to healthcare institutions, private hospitals, medical clinics and clinical laboratories licensed under the Private Hospitals and Medical Clinics (PHMC) Act in Singapore.

VereRTCoV™ SARS-CoV-2 Real-Time RT-PCR 2.0 is a one-step Reverse Transcription Polymerase Chain Reaction (RT-PCR)-based IVD test intended for the qualitative detection of nucleic acid belonging to SARS-CoV-2. This test is suitable and easily adaptable for use in qPCR cycler with FAM and HEX (HIC) detection channels.

Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories said, “In response to this COVID-19 pandemic situation, our team worked rapidly to develop an updated with increased sensitivity and user friendliness real-time RT-PCR test to detect SARS-CoV-2. This updated assay provides enhanced tolerance against gene mutations by targeting dual viral N gene targets as well as an inclusion of the human RPP30 gene as the Human Internal Control within the assay. We are proud and excited to receive this Provisional Authorisation IVD from HSA and for Veredus to support laboratories in their diagnostic effort for COVID-19.

Learn more > https://vereduslabs.com/covid-19/

Singapore HSA issued Veredus Laboratories with Provisional Authorisation for LIONRUN Diagnostic Kit for Antibody IgM/IgG of Novel Coronavirus COVID-19 for In vitro Diagnostic (IVD) use

Veredus Laboratories Pte Ltd “Veredus” announced today that it has received Provisional Authorisation from Singapore Health Sciences Authority (HSA) for LIONRUN Diagnostic Kit for Antibody IgM/IgG of Novel Coronavirus COVID-19 “LIONRUN Antibody Kit”. Veredus can supply to the healthcare institutions, private hospitals, medical clinics or clinical laboratories licensed under the PHMC Act (Cap. 248) for use on their patients.
LIONRUN Antibody Kit is a colloidal gold IgM/IgG immunochromatography antibody test and is intended for the qualitative and differential detection of IgM and IgG antibodies against the 2019 novel Coronavirus (2019-nCoV) also known as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in human whole blood, serum or plasma, capable of providing test results in 10 minutes. LIONRUN Antibody Kit is a product manufactured by Shanghai LiangRun Biomedicine Technology Co. Ltd.
Dr Rosemary Tan, CEO of Veredus Laboratories said “We are proud to receive this Provisional Authorisation for LIONRUN Antibody Kit to be used directly on patients in Singapore as an alternative to molecular laboratory testing. This lays a path for clinical testing to be performed outside a central laboratory where local communities can be screened at frontline and triage centers in a time- and cost-effective manner.”

Veredus Laboratories Announces CE-IVD Marking of VereCoV™ Detection Kit for Diagnosis of COVID-19

Veredus Laboratories Pte Ltd “Veredus” today announced the CE-IVD marking of VereCoV™ Detection Kit for commercial launch in Europe. The test is intended for the qualitative detection of 2019 novel Coronavirus (2019-nCoV) also known as SARSCoV- 2 that causes COVID-19.


The kit was developed to provide an easy-to-use solution for clinical testing, public health surveillance and detection of the coronavirus from nasal or nasopharyngeal swab specimen to enable authorities to take appropriate actions. The test integrates PCR amplification and microarray for rapid qualitative detection of 2019-nCoV with the additional capability to detect a subset of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) simultaneously with the same test.


“We are ready to respond effectively to the needs of hospitals and reference laboratories by providing a quality molecular testing solution for the pandemic,” says Dr Rosemary Tan, Chief Executive Officer of Veredus Laboratories.